Philip E. Hass

8.4k total citations · 3 hit papers
36 papers, 5.6k citations indexed

About

Philip E. Hass is a scholar working on Molecular Biology, Immunology and Hematology. According to data from OpenAlex, Philip E. Hass has authored 36 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Immunology and 12 papers in Hematology. Recurrent topics in Philip E. Hass's work include Complement system in diseases (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Platelet Disorders and Treatments (7 papers). Philip E. Hass is often cited by papers focused on Complement system in diseases (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Platelet Disorders and Treatments (7 papers). Philip E. Hass collaborates with scholars based in United States, France and Switzerland. Philip E. Hass's co-authors include Bharat B. Aggarwal, Thomas E. Eessalu, Irene S. Figari, Michael A. Palladino, H. Michael Shepard, Barry J. Sugarman, Dan Eaton, Walter C. Darbonne, Frédéric J. de Sauvage and David V. Goeddel and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Philip E. Hass

36 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro

1985 1.4k citations Barry J. Sugarman, Bharat B. Aggarwal et al. Science profile →
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand

1994 1.1k citations Philip E. Hass, Dan Eaton et al. Nature profile →
Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon

1985 781 citations Bharat B. Aggarwal, Philip E. Hass et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip E. Hass United States	24	2.1k	1.8k	1.7k	686	616	36	5.6k
P Ralph United States	43	2.9k 1.4×	2.0k 1.1×	1.3k 0.8×	1.2k 1.7×	543 0.9×	77	5.9k
Yasusada Miura Japan	41	2.6k 1.2×	2.3k 1.3×	2.1k 1.2×	1.6k 2.3×	517 0.8×	280	7.3k
Richard J. Riese United States	36	2.2k 1.1×	1.6k 0.9×	1.0k 0.6×	1.1k 1.6×	500 0.8×	76	7.2k
Louis M. Pelus United States	47	2.3k 1.1×	2.5k 1.4×	2.0k 1.1×	1.8k 2.7×	394 0.6×	159	6.3k
DW Golde United States	45	2.4k 1.1×	1.6k 0.9×	2.0k 1.1×	1.1k 1.6×	563 0.9×	126	6.2k
F. Herrmann Germany	40	2.3k 1.1×	1.4k 0.7×	2.0k 1.1×	1.5k 2.2×	573 0.9×	149	5.6k
Paschalis Sideras Sweden	40	4.8k 2.3×	1.8k 1.0×	812 0.5×	837 1.2×	840 1.4×	79	7.3k
T Hirano Japan	36	2.9k 1.4×	1.4k 0.7×	973 0.6×	1.9k 2.8×	423 0.7×	117	6.1k
G. S. Hodgson Australia	35	2.6k 1.3×	1.6k 0.8×	1.6k 0.9×	1.3k 1.9×	632 1.0×	107	5.8k
M P Beckmann United States	33	3.8k 1.8×	1.9k 1.0×	842 0.5×	1.7k 2.4×	457 0.7×	44	6.9k

Countries citing papers authored by Philip E. Hass

Since Specialization

Citations

This map shows the geographic impact of Philip E. Hass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip E. Hass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip E. Hass more than expected).

Fields of papers citing papers by Philip E. Hass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip E. Hass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip E. Hass. The network helps show where Philip E. Hass may publish in the future.

Co-authorship network of co-authors of Philip E. Hass

This figure shows the co-authorship network connecting the top 25 collaborators of Philip E. Hass. A scholar is included among the top collaborators of Philip E. Hass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip E. Hass. Philip E. Hass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shatz-Binder, Whitney, Philip E. Hass, Maciej Paluch, et al.. (2019). Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye. PLoS ONE. 14(6). e0218613–e0218613. 21 indexed citations

Loyet, Kelly M., Philip E. Hass, Wendy Sandoval, et al.. (2018). In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Molecular Pharmaceutics. 16(1). 86–95. 6 indexed citations

Tesar, Devin B., Whitney Shatz-Binder, Philip E. Hass, et al.. (2017). Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. mAbs. 9(8). 1297–1305. 13 indexed citations

Ramani, Sree R., Jason A. Hackney, Irene Tom, et al.. (2016). The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation. Nature Communications. 7(1). 11473–11473. 37 indexed citations

Couch, Jessica A., Gu Zhang, Joseph C. Beyer, et al.. (2015). Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation. Clinical Cancer Research. 22(6). 1469–1479. 20 indexed citations

Dickmann, Leslie J., Victor Yip, Mauricio Maia, et al.. (2015). Evaluation of Fluorophotometry to Assess the Vitreal Pharmacokinetics of Protein Therapeutics. Investigative Ophthalmology & Visual Science. 56(11). 6991–6991. 21 indexed citations

Olsen, Olav, Dara Kallop, Todd McLaughlin, et al.. (2014). Genetic Analysis Reveals that Amyloid Precursor Protein and Death Receptor 6 Function in the Same Pathway to Control Axonal Pruning Independent of β-Secretase. Journal of Neuroscience. 34(19). 6438–6447. 44 indexed citations

Loyet, Kelly M., Xiangdan Wang, Jihong Yang, et al.. (2014). Complement Inhibition in Cynomolgus Monkeys by Anti–Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration. Journal of Pharmacology and Experimental Therapeutics. 351(3). 527–537. 40 indexed citations

Katschke, Kenneth J., Ping Wu, Rajkumar Ganesan, et al.. (2012). Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite. Journal of Biological Chemistry. 287(16). 12886–12892. 66 indexed citations

10.

Chih, Ben, Peter Liu, Cécile Chalouni, et al.. (2011). A ciliopathy complex at the transition zone protects the cilia as a privileged membrane domain. Nature Cell Biology. 14(1). 61–72. 270 indexed citations

11.

Campagne, Menno van Lookeren, Kenneth J. Katschke, Ping Wu, et al.. (2010). Targeting the Alternative Pathway of Complement in AMD With a Factor D Selective Antibody. Investigative Ophthalmology & Visual Science. 51(13). 4511–4511. 2 indexed citations

12.

Katschke, Kenneth J., Scott Stawicki, Jianping Yin, et al.. (2009). Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement. Journal of Biological Chemistry. 284(16). 10473–10479. 48 indexed citations

13.

Katschke, Kenneth J., Karim Y. Helmy, Micah Steffek, et al.. (2007). A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. The Journal of Experimental Medicine. 204(6). 1319–1325. 76 indexed citations

14.

Wiesmann, Christian, Kenneth J. Katschke, Jianping Yin, et al.. (2006). Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature. 444(7116). 217–220. 187 indexed citations

15.

Deng, Bijia, Naheed Banu, Philip E. Hass, et al.. (1998). An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis. Blood. 92(6). 1981–1988. 29 indexed citations

16.

Kunitake, S T, Stephen G. Young, Clive R. Pullinger, et al.. (1990). Conformation of apolipoprotein B-100 in the low density lipoproteins of tangier disease. Identification of localized conformational response to triglyceride content.. Journal of Biological Chemistry. 265(34). 20739–20746. 29 indexed citations

17.

Drayna, Dennis, Robert A. Hegele, Philip E. Hass, et al.. (1988). Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene. Genomics. 3(3). 230–236. 71 indexed citations

18.

Eaton, Dan, William I. Wood, Debbie Eaton, et al.. (1986). Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry. 25(26). 8343–8347. 244 indexed citations

19.

Sugarman, Barry J., Bharat B. Aggarwal, Philip E. Hass, et al.. (1985). Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in Vitro. Science. 230(4728). 943–945. 1402 indexed citations breakdown →

20.

Wada, Hiroshi, et al.. (1979). Transferrin Receptor in Human Placental Brush Border Membranes. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact